Hyperfine Announces Enrollment of First Patient in Study to Expand Intended Use of the Swoop® System with Contrast Agents

The prospective study is designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI to support an FDA 510(k) submission. GUILFORD, Conn. --(BUSINESS WIRE)--Jan. 15, 2026-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology